Influenza vaccine production technologies: past, present and future
Yingxia Wen A and Ethan C Settembre A B
+ Author Affiliations
- Author Affiliations
A Seqirus, A CSL Company
50 Hampshire Street
Cambridge, MA 02139, USA
B Tel: 1 617 254 5354 Email: Ethan.Settembre@Seqirus.com
Microbiology Australia 38(2) 52-54 https://doi.org/10.1071/MA17026
Published: 21 March 2017
Abstract
Influenza is a constantly evolving global health threat that leads to substantial morbidity and mortality particularly in vulnerable populations at either end of the age spectrum. Society has responded by creating a global public-private system that involves constant surveillance, candidate virus generation, and release reagent generation linked to worldwide influenza vaccine manufacturing capabilities. It was initially recognised that influenza circulates as multiple antigenically distinct subtypes, which led to the generation of vaccines containing multiple influenza strains. The first and still current major process used for influenza vaccine production is infection of embryonated hen's eggs with influenza virus. While this approach was a true advancement, some shortcomings such as lack of vaccine match to circulating strains due to egg adaptation and production capacity limitations have led to recent innovations in mammalian cell production and synthetic technologies aimed at further improving global influenza responses.
References
[1] Poland, G.A. et al. (2001) Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 19, 2216–2220.| Influenza vaccines: a review and rationale for use in developed and underdeveloped countries.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3MvgvFSmtA%3D%3D&md5=0446f485cc4242f18e6949fec8f62a9cCAS |
[2] Pereyaslov, D. et al. (2016) Improving the representativeness of influenza viruses shared within the WHO Global Influenza Surveillance and Response System. Influenza Other Resp. Viruses 10, 68–75.
| Improving the representativeness of influenza viruses shared within the WHO Global Influenza Surveillance and Response System.Crossref | GoogleScholarGoogle Scholar |
[3] Oxford, J.S. et al. (1991) Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition. J. Gen. Virol. 72, 185–189.
| Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition.Crossref | GoogleScholarGoogle Scholar |
[4] Robertson, J.S. et al. (1985) Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143, 166–174.
| Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaL2MXitVSqt7c%3D&md5=4534dab6adba72c97623668f8aa8acbfCAS |
[5] Wood, J.M. et al. (1989) H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 171, 214–221.
| H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaL1MXkvFGjtbo%3D&md5=e44e0b4b653b0135273aff98ffe89f9cCAS |
[6] Rocha, E.P. et al. (1993) Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J. Gen. Virol. 74, 2513–2518.
| Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2cXisVOgtg%3D%3D&md5=0087e02d661c6ad1a11e032a6ccde2cdCAS |
[7] Wang, M.L. et al. (1989) Extensive heterogeneity in the hemagglutinin of egg-grown influenza viruses from different patients. Virology 171, 275–279.
| Extensive heterogeneity in the hemagglutinin of egg-grown influenza viruses from different patients.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaL1MXkslKjtLc%3D&md5=ce164f71d25dd791522f15ad305d8b2dCAS |
[8] Katz, J.M. and Webster, R.G. (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160, 191–198.
| Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaL1MzktFCmtA%3D%3D&md5=04440e945896597f05fa9de28b3102b5CAS |
[9] Alymova, I.V. et al. (1998) Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. J. Virol. 72, 4472–4477.
| 1:CAS:528:DyaK1cXis1Kmtr0%3D&md5=b993d044a992ffd06c18077b0cbfa614CAS |
[10] Frey, S. et al. (2010) Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis. 51, 997–1004.
| Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults.Crossref | GoogleScholarGoogle Scholar |
[11] Settembre, E.C. et al. (2014) Bringing influenza vaccines into the 21st century. Hum. Vaccin. Immunother. 10, 600–604.
| Bringing influenza vaccines into the 21st century.Crossref | GoogleScholarGoogle Scholar |
[12] Jin, H. and Chen, Z. (2014) Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses. Curr. Opin. Virol. 6, 34–39.
| Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXhtVarsLnN&md5=a8401958eaac7dbe772e869904be008bCAS |
[13] Dormitzer, P.R. et al. (2013) Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci. Transl. Med. 5, 185ra68.
| Synthetic generation of influenza vaccine viruses for rapid response to pandemics.Crossref | GoogleScholarGoogle Scholar |
[14] Geall, A.J. et al. (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109, 14604–14609.
| Nonviral delivery of self-amplifying RNA vaccines.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhsVaqu7zI&md5=d33f67e640e92a8fd96087247767a391CAS |
[15] Hekele, A. et al. (2013) Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2, e52.
| Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice.Crossref | GoogleScholarGoogle Scholar |
